
Eli N Deal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7976007/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Predictors of Treatment Failure Following De-escalation to a Fluoroquinolone in Culture-Negative Nosocomial Pneumonia. Annals of Pharmacotherapy, 2019, 53, 1207-1213.	1.9	1
2	Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation. Journal of the American Society of Nephrology: JASN, 2017, 28, 1957-1959.	6.1	6
3	Weightâ€based insulin dosing for acute hyperkalemia results in less hypoglycemia. Journal of Hospital Medicine, 2016, 11, 355-357.	1.4	34
4	Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients. Annals of Pharmacotherapy, 2016, 50, 824-831.	1.9	4
5	Impact of Vitamin K Administration on INR Changes and Bleeding Events Among Patients With Cirrhosis. Annals of Pharmacotherapy, 2016, 50, 113-117.	1.9	20
6	Analysis of Enoxaparin Dose Titration at a Large, Tertiary Teaching Facility. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 720-723.	1.7	0
7	Apixaban Use Among Patients With Severe Renal Impairment. Annals of Pharmacotherapy, 2014, 48, 1667-1667.	1.9	23
8	Safety and Efficacy of Hyperglycemia Urgency Order Set. Journal of Diabetes Science and Technology, 2014, 8, 1062-1063.	2.2	0
9	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and Haemostasis, 2014, 111, 88-93.	3.4	120
10	Consider a Patient's Weight and the Weight of the Evidence When Calculating Renal Function. Annals of Pharmacotherapy, 2013, 47, 908-909.	1.9	4
11	Assessment of Bleeding Events Associated With Short-Duration Therapeutic Enoxaparin Use in the Morbidly Obese. Annals of Pharmacotherapy, 2013, 47, 1641-1648.	1.9	11
12	Role of New Drugs for Management of Atrial Fibrillation. Annals of Pharmacotherapy, 2012, 46, 1656-1670.	1.9	2
13	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients Blood, 2012, 120, 2268-2268.	1.4	0
14	Implementation of a real-time computerized sepsis alert in nonintensive care unit patients*. Critical Care Medicine, 2011, 39, 469-473.	0.9	145
15	Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. Journal of Thrombosis and Thrombolysis, 2011, 32, 188-194.	2.1	36
16	Inpatient insulin orders: Are patients getting what is prescribed?. Journal of Hospital Medicine, 2011, 6, 526-529.	1.4	18
17	Comparison of Bivalirudin and Argatroban for the Management of Heparinâ€Induced Thrombocytopenia. Pharmacotherapy, 2010, 30, 1229-1238.	2.6	52
18	Identifying Optimal Initial Infusion Rates for Unfractionated Heparin in Morbidly Obese Patients. Annals of Pharmacotherapy, 2010, 44, 1141-1151.	1.9	41

Eli N Deal

#	Article	IF	CITATIONS
19	Characteristics of patients with morbid obesity at an academic medical center. American Journal of Health-System Pharmacy, 2010, 67, 1589-1590.	1.0	7
20	Reply: Identifying Optimal Initial Infusion Rates for Unfractionated Heparin in Morbidly Obese Patients. Annals of Pharmacotherapy, 2010, 44, 2038-2039.	1.9	0
21	Contraindicated Medication Use in Dialysis Patients. JAMA - Journal of the American Medical Association, 2010, 303, 1481-1482.	7.4	1
22	Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: A single-center, open-label, prospective, observational study. Clinical Therapeutics, 2009, 31, 299-310.	2.5	12
23	Role of corticosteroids in the management of acute respiratory distress syndrome. Clinical Therapeutics, 2008, 30, 787-799.	2.5	36
24	Delayed-Onset Neutropenia with Divalproex Sodium. Annals of Pharmacotherapy, 2008, 42, 1507-1510.	1.9	14
25	Predictors of In-Hospital Mortality for Bloodstream Infections Caused byEnterobacterSpecies orCitrobacter freundii. Pharmacotherapy, 2007, 27, 191-199.	2.6	37